These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 21040217

  • 21. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 22. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct 15; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 23. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E, Deschesnes RG, Côté MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C -Gaudreault R.
    Cancer Res; 2004 Jul 01; 64(13):4654-63. PubMed ID: 15231678
    [Abstract] [Full Text] [Related]

  • 24. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.
    Clin Cancer Res; 2001 May 01; 7(5):1429-37. PubMed ID: 11350914
    [Abstract] [Full Text] [Related]

  • 25. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor.
    Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, Hong SI, Eun CK, Zhang W, Rhee CH.
    Int J Oncol; 2003 Jun 01; 22(6):1271-6. PubMed ID: 12738993
    [Abstract] [Full Text] [Related]

  • 26. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 27. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
    Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, Pervin A, Tseng B, Carlson RO, Pleiman CM.
    Cancer Res; 2007 Jun 15; 67(12):5865-71. PubMed ID: 17575155
    [Abstract] [Full Text] [Related]

  • 28. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.
    Cancer Res; 2003 Nov 01; 63(21):7301-9. PubMed ID: 14612527
    [Abstract] [Full Text] [Related]

  • 29. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.
    Mohan R, Banerjee M, Ray A, Manna T, Wilson L, Owa T, Bhattacharyya B, Panda D.
    Biochemistry; 2006 May 02; 45(17):5440-9. PubMed ID: 16634625
    [Abstract] [Full Text] [Related]

  • 30. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
    Beckers T, Reissmann T, Schmidt M, Burger AM, Fiebig HH, Vanhoefer U, Pongratz H, Hufsky H, Hockemeyer J, Frieser M, Mahboobi S.
    Cancer Res; 2002 Jun 01; 62(11):3113-9. PubMed ID: 12036922
    [Abstract] [Full Text] [Related]

  • 31. Identification and characterization of A-105972, an antineoplastic agent.
    Wu-Wong JR, Alder JD, Alder L, Burns DJ, Han EK, Credo B, Tahir SK, Dayton BD, Ewing PJ, Chiou WJ.
    Cancer Res; 2001 Feb 15; 61(4):1486-92. PubMed ID: 11245455
    [Abstract] [Full Text] [Related]

  • 32. Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
    Prinz H, Ishii Y, Hirano T, Stoiber T, Camacho Gomez JA, Schmidt P, Düssmann H, Burger AM, Prehn JH, Günther EG, Unger E, Umezawa K.
    J Med Chem; 2003 Jul 17; 46(15):3382-94. PubMed ID: 12852768
    [Abstract] [Full Text] [Related]

  • 33. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
    Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM, Chen SP, Chang WL, Harn HJ.
    Biochem Pharmacol; 2006 Jul 28; 72(3):308-19. PubMed ID: 16782069
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. BPR0C261, An Analogous of Microtubule Disrupting Agent D-24851 Enhances the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells via p53-Dependent and p53-Independent Pathways.
    Leu JD, Lin ST, Chen CT, Chang CA, Lee YJ.
    Int J Mol Sci; 2022 Nov 15; 23(22):. PubMed ID: 36430560
    [Abstract] [Full Text] [Related]

  • 36. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
    Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD.
    Clin Cancer Res; 2008 Oct 01; 14(19):6218-27. PubMed ID: 18829501
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. MONCPT exerts anti-cancer activities via inducing G2/M arrest and apoptosis in human bladder cancer.
    Zhu Y, Jiang H, Zhang C, He QJ, Yang B, Li LJ, Zhu H.
    Pharmazie; 2009 Dec 01; 64(12):823-8. PubMed ID: 20095141
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
    Boumendjel A, Boccard J, Carrupt PA, Nicolle E, Blanc M, Geze A, Choisnard L, Wouessidjewe D, Matera EL, Dumontet C.
    J Med Chem; 2008 Apr 10; 51(7):2307-10. PubMed ID: 18293907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.